KBEW – The Information Station
    • Homepage
FibroBiologics Compliant with All Nasdaq Listing Requirements

Author: FibroBiologics, Inc.

Posted Date:

April 20, 2026
  • FibroBiologics Compliant with All Nasdaq Listing Requirements

    FibroBiologics, Inc.
    April 20, 2026
  • FibroBiologics Announces Closing of $3 Million Public Offering

    FibroBiologics, Inc.
    April 2, 2026
  • FibroBiologics Announces Pricing of $3 Million Public Offering

    FibroBiologics, Inc.
    March 31, 2026
  • FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

    FibroBiologics, Inc.
    March 31, 2026
  • FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

    FibroBiologics, Inc.
    March 25, 2026
  • FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

    FibroBiologics, Inc.
    March 12, 2026
  • FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

    FibroBiologics, Inc.
    March 5, 2026
  • FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

    FibroBiologics, Inc.
    March 2, 2026
  • FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

    FibroBiologics, Inc.
    February 24, 2026
  • FibroBiologics Granted Extension by Nasdaq to Regain Compliance

    FibroBiologics, Inc.
    February 23, 2026
1 2
Next